Managed Access Programs for LEE011, Ribociclib

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

NCT03096847 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

NCT03671330 ·Status: COMPLETED ·Phase: PHASE2

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

NCT02422615 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

NCT02657343 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of LY3007113 in Participants With Advanced Cancer

NCT01463631 ·Status: COMPLETED ·Phase: PHASE1

Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer

NCT02632045 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

NCT07237256 ·Status: RECRUITING ·Phase: PHASE3

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

NCT03078751 ·Status: COMPLETED ·Phase: PHASE2

A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer

NCT03956654 ·Status: COMPLETED

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

NCT06797531 ·Status: RECRUITING

Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC

NCT02941926 ·Status: COMPLETED ·Phase: PHASE3

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

NCT01857193 ·Status: COMPLETED ·Phase: PHASE1

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

NCT05569187 ·Status: COMPLETED

Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer

NCT04473040 ·Status: AVAILABLE

A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer

NCT07086196 ·Status: COMPLETED

Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

NCT05697146 ·Status: ACTIVE_NOT_RECRUITING

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

NCT02088684 ·Status: COMPLETED ·Phase: PHASE1

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

NCT03763604 ·Status: APPROVED_FOR_MARKETING

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

NCT03081234 ·Status: WITHDRAWN ·Phase: PHASE3

Ribociclib and Bicalutamide in AR+ TNBC

NCT03090165 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Real-world Outcomes Among Patients Treated With Ribociclib

NCT07148505 ·Status: COMPLETED

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949 ·Status: COMPLETED ·Phase: PHASE1

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

NCT02154776 ·Status: COMPLETED ·Phase: PHASE1

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

NCT06587789 ·Status: RECRUITING